New CAR T-Cell therapy offers hope for Hard-to-Treat lymphoma patients
NCT ID NCT07319676
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to other treatments. About 30 participants will receive immune cells engineered to target their cancer. The goal is to find the safest and most effective dose and see how well it controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore, 119228, Singapore
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.